- Home
- ZENV vs ONCY Comparison
ZENV vs ONCY Comparison
Compare ZENV & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- ONCY
- Stock Information
- Founded
- ZENV 2005
- ONCY 1998
- Country
- ZENV Brazil
- ONCY Canada
- Employees
- ZENV N/A
- ONCY N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- ONCY Pharmaceuticals and Biotechnology
- Sector
- ZENV Technology
- ONCY Health Care
- Exchange
- ZENV Nasdaq
- ONCY Nasdaq
- Market Cap
- ZENV 79.7M
- ONCY 89.7M
- IPO Year
- ZENV 2021
- ONCY 1999
- Fundamental
- Price
- ZENV $1.18
- ONCY $1.37
- Analyst Decision
- ZENV
- ONCY Strong Buy
- Analyst Count
- ZENV 0
- ONCY 5
- Target Price
- ZENV N/A
- ONCY $5.00
- AVG Volume (30 Days)
- ZENV 91.5K
- ONCY 1.2M
- Earning Date
- ZENV 09-10-2025
- ONCY 11-11-2025
- Dividend Yield
- ZENV N/A
- ONCY N/A
- EPS Growth
- ZENV N/A
- ONCY N/A
- EPS
- ZENV N/A
- ONCY N/A
- Revenue
- ZENV $201,426,369.00
- ONCY N/A
- Revenue This Year
- ZENV $6.49
- ONCY N/A
- Revenue Next Year
- ZENV $3.82
- ONCY N/A
- P/E Ratio
- ZENV N/A
- ONCY N/A
- Revenue Growth
- ZENV 24.80
- ONCY N/A
- 52 Week Low
- ZENV $1.02
- ONCY $0.33
- 52 Week High
- ZENV $3.03
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- ZENV 34.63
- ONCY 64.74
- Support Level
- ZENV $1.13
- ONCY $1.20
- Resistance Level
- ZENV $1.85
- ONCY $1.44
- Average True Range (ATR)
- ZENV 0.11
- ONCY 0.11
- MACD
- ZENV -0.05
- ONCY 0.01
- Stochastic Oscillator
- ZENV 6.94
- ONCY 82.56
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.